Hyperuricaemia - febuxostat
Febuxostat for the management of hyperuricaemia in people with gout
Summary
Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout only if: they can't take the medicine allopurinol for medical reasons or the side effects of allopurinol are so bad that the person either has to stop taking it or can't be given the most effective ...
The manufacturer has informed NICE that it is temporarily unable to make the drug available. On the basis of advice from NICE, Ministers have therefore agreed to waive the direction requiring NHS organisations to make funding available for NICE recommended treatments within three months of final guidance for this appraisal. The funding direction will be reinstated once the drug is available. Further information can be found on the Department of Health website.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in August 2011
About this guidance
Technology appraisals TA164
Issued: December 2008
How this guidance was produced